Loading…
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $19M | $-91M | $-82M | $-70M | -28.9% | - | 65.0% |
| 2024 | $0M | $-59M | $-50M | $-60M | -24.4% | - | -28.9% |
| 2023 | $0M | $-72M | $-70M | $-60M | 75.5% | -100.0% | 547.2% |
| 2022 | $15M | $-10M | $-11M | $-4M | 44.7% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 15 | 0 | 0 | 19.09 |
| Operating Revenue | - | 15 | 0 | 0 | 19.09 |
| Cost Of Revenue | - | - | - | 0 | 0.42 |
| Gross Profit | - | - | - | 0 | 18.67 |
| Operating Expense | - | 25.48 | 72.43 | 58.61 | 109.81 |
| Research And Development | - | 21.12 | 59.50 | 29.80 | 18.67 |
| Selling General And Administration | - | 4.36 | 12.92 | 28.81 | 91.14 |
| Total Expenses | - | 25.48 | 72.43 | 58.61 | 110.23 |
| Operating Income | - | -10.48 | -72.43 | -58.61 | -91.14 |
| Total Operating Income As Reported | - | -10.48 | -72.43 | -58.61 | -91.14 |
| EBITDA | - | -10.48 | -72.41 | -58.55 | -90.85 |
| Normalized EBITDA | - | -10.48 | -72.41 | -58.55 | -90.85 |
| EBIT | - | -10.48 | -72.43 | -58.61 | -91.14 |
| Interest Income | - | - | 2.19 | 8.55 | 9.76 |
| Net Interest Income | - | - | 2.19 | 8.55 | 9.76 |
| Other Non Operating Income Expenses | - | 0.02 | 0.09 | 0.29 | -0.24 |
| Other Income Expense | - | 0.02 | 0.09 | 0.29 | -0.24 |
| Interest Income Non Operating | - | - | 2.19 | 8.55 | 9.76 |
| Net Non Operating Interest Income Expense | - | - | 2.19 | 8.55 | 9.76 |
| Pretax Income | - | -10.46 | -70.15 | -49.77 | -81.62 |
| Tax Provision | - | 0.35 | -0.18 | 0 | 0.50 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -10.81 | -69.97 | -49.77 | -82.13 |
| Net Income From Continuing And Discontinued Operation | - | -10.81 | -69.97 | -49.77 | -82.13 |
| Net Income From Continuing Operation Net Minority Interest | - | -10.81 | -69.97 | -49.77 | -82.13 |
| Net Income | - | -10.81 | -69.97 | -49.77 | -82.13 |
| Net Income Common Stockholders | - | -10.81 | -69.97 | -49.77 | -82.13 |
| Net Income Including Noncontrolling Interests | - | -10.81 | -69.97 | -49.77 | -82.13 |
| Normalized Income | - | -10.81 | -69.97 | -49.77 | -82.13 |
| Diluted NI Availto Com Stockholders | - | -10.81 | -69.97 | -49.77 | -82.13 |
| Basic Average Shares | - | 25.53 | 25.53 | 21.28 | 28.81 |
| Diluted Average Shares | - | 25.53 | 25.53 | 21.28 | 28.81 |
| Reconciled Depreciation | - | 0.01 | 0.02 | 0.06 | 0.29 |
| Reconciled Cost Of Revenue | - | - | - | 0 | 0.42 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| LENZ Therapeutics, Inc.this co. | LENZ | $226M | - | 0.79 | -28.9% | - |
| LifeMD, Inc. | LFMD | $236M | 16.41 | 10.17 | 62.0% | -135.17 |
| Arcturus Therapeutics Holdings Inc. | ARCT | $229M | -3.47 | 1.07 | -30.7% | -0.36 |
| Spok Holdings, Inc. | SPOK | $228M | 14.38 | 1.56 | 10.8% | 8.90 |
| Fulcrum Therapeutics, Inc. | FULC | $225M |
| - |
| - |
| - |
| - |
| - |
| 0.64 |
| -21.5% |
| - |
| Foghorn Therapeutics Inc. | FHTX | $220M | -2.96 | -2.02 | 68.5% | -2.28 |
| Inhibikase Therapeutics, Inc. | IKT | $219M | -4.54 | 1.27 | -27.9% | -1.50 |
| Voyager Therapeutics, Inc. | VYGR | $219M | -1.83 | 1.12 | -61.1% | -1.49 |
| Utah Medical Products, Inc. | UTMD | $216M | 19.17 | 1.82 | 9.5% | 9.09 |
| Peer Median | - | -1.83 | 1.19 | -6.0% | -1.49 | |